Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease

Diabetes Research and Clinical Practice

Volumn 94, Issue 2, 2011, Pages 167-171

  Hara, Katsuko ^a   Hirowatari, Yuji ^b   Shimura, Yuko ^b   Takahashi, Hakuo ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b TOSOH CORPORATION   (Japan)

Author keywords

Atherosclerosis; Diabetes mellitus; HPLC; Platelet; Serotonin

Indexed keywords

SEROTONIN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE POOR PLASMA;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY; MALE; MIDDLE AGED; PLATELET ACTIVATION; SEROTONIN; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 81255185074     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.06.020     Document Type: Article

References (17)

1. Chade A.R., Lerman A., Lerman L.O. Kidney in early atherosclerosis. Hypertension 2005, 45:1042-1049.
2. Natarajan R., Nadler J.L. Lipid inflammatory mediators in diabetic vascular disease. Atheroscler Thromb Vasc Biol 2004, 24:1542-1548.
3. Fan J., Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003, 10:63-71.
4. Gimbrone M.A., Topper J.N., Nagel T., Anderson K.R., Garcia-Cardeña G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000, 902:230-239.
5. Fareed J., Hoppensteadt D.A., Leya F., Lewis B., Callas D., Wolf H., et al. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998, 44:1845-1853.
6. Ohkawa R., Hirowatari Y., Nakamura K., Ohkubo S., Ikeda H., Okada M.M., et al. Platelet release of beta-thromboglobulin and platelet factor 4 and serotonin in plasma samples. Clin Biochem 2005, 38:1023-1026.
7. Hirowatari Y., Hara K., Kamihata H., Iwasaka T., Takahashi H. High-performance liquid chromatographic method with column-switching and post-column reaction for determination of serotonin levels in platelet-poor plasma. Clin Biochem 2004, 37:191-197.
8. Hara K., Hirowatari Y., Yoshika M., Komiyama Y., Tsuka Y., Takahashi H. The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. J Lab Clin Med 2004, 144:31-37.
9. Sirek A., Sirek O.V. Serotonin: a review. Can Med Assoc J 1970, 102:846-849.
10. Barradas M.A., Gill D.S., Fonseca V.A., Mikhailidis D.P., Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988, 18:399-404.
11. Pietraszek M.H., Takada Y., Takada A., Fujita M., Watanabe I., Taminato A., et al. Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1992, 66:765-774.
12. Martín F.J., Míguez J.M., Aldegunde M., Atienza G. Effect of streptozotocin-induced diabetes mellitus on serotonin measures of peripheral tissues in rats. Life Sci 1995, 56:51-59.
13. Martín F.J., Míguez J.M., Aldegunde M., Atienza G. Platelet serotonin transport is altered in streptozotocin-induced diabetic rats. Life Sci 1995, 56:1807-1815.
14. Cićin-Sain L., Jernej B. Reduction of gastrointestinal serotonin in alloxan-diabetic rats: reversal by 5-hydroxytryptophan treatment. Behav Brain Res 1996, 73:285-288.
15. Blardi P., de Lalla A., Pieragalli D., De Franco V., Meini S., Ceccatelli L., et al. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. Prostaglandins Other Lipid Mediat 2006, 80:175-182.
16. Fukui M., Shiraishi E., Tanaka M., Senmaru T., Sakabe K., Harusato I., et al. Plasma serotonin is a predictor for deterioration of urinary albumin excretion in men with type 2 diabetes mellitus. Metabolism 2009, 58:1076-1079.
17. Haraguchi T., Koga N., Higashi K., Kobori S. Sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. Diabetes Res Clin Pract 2002, 58:123-129.